Adam Johnson is the founder of BullseyeBrief.com, an investment letter which explores American Ingenuity through actionable stock picks. Previously he anchored several daily programs at Bloomberg TV, interviewing CEOs, heads of state, and prominent investors. Mr. Johnson also traded stocks, options, and oil at ING Asset Management, Louis Dreyfus, and Merrill Lynch. He graduated from Princeton with a BA in economics.
I’ve had precious little personal experience with cannabis, but an increasingly cannabis-friendly Capital Hill makes me think it’s time to educate myself, asserts Adam Johnson, editor of Bullseye Brief.
Nine Meters Biopharma (NMTR) is a biotechnology company focusing on patients with gastrointestinal issues for which no treatments currently exist, explains Adam Johnson, growth stock expert and editor of Bullseye Brief.
A newly formed company has already successfully enabled several dozen drug development projects to move forward in a virtual setting, creating a blueprint for transforming the $60B clinical trial industry, notes Adam Johnson, editor of Bullseye Brief.
US GDP growth is surging to a 40-year high of 6.5%, and economists tracked by Bloomberg estimate the rate could double by June, before settling in the mid-single digits through next year, observes Adam Johnson, editor of Bullseye Brief.
How we move is changing fast and it's not about building a faster Tesla. 30-ft drones transport US Air Force personnel across sprawling bases. Fuel cells power construction equipment, lifting thousands of pounds. Electric delivery vans make UPS greener and our air cleaner. Several pioneering companies are propelling the world forward at record speed. The question is which ones to buy today? Join Adam Johnson to discover how the future of mobility is now.
SpaceX made history with the launch into orbit of the first manned space capsule by a private company. While we may not be vacationing in Mars any time soon, we are living in a world where technology is evolving faster than ever. In this panel discussion, get up to speed on the latest trends in the industry, explore breakthrough technologies, and hear about the most innovative disruptors reshaping the future.
Tune in to this 30-minute session to discuss several Med-Tech hybrid companies as case studies, explaining how they're redefining health and moving the world forward. Adam Johnson is long on all of them, and see's significant upside. "Health Care's Holy Grail" is his biggest investment theme for 2021, thanks to the convergence of wearables, AI, 5G, and telemedicine, and he's excited to share with you what he has learned!
Biotechnology offers significant upside if you know where to look. Adam Johnson, founder of BullseyeBrief.com, shares his three favorite biotech stocks under $3, why he's long and what he expects. These are some of the best examples of American Ingenuity!